Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.

深圳市海普瑞藥業集團股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 9989)

2023 THIRD QUARTERLY REPORT

Reporting Period

Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Li Li
Chairman

As at the date of this announcement, the executive directors of the Company are Mr. Li Li, Ms. Li Tan, Mr. Shan Yu and Mr. Zhang Ping; and the independent non-executive directors of the Company are Dr. Lu Chuan, Mr. Huang Peng and Mr. Yi Ming.

IMPORTANT NOTICE:

I. KEY FINANCIAL INFORMATION

(1) Major Accounting Information and Financial Indicators

‰ ‰

Currency: RMB Unit: Yuan

	The third quarter of 2023	Increase/ decrease for the third quarter of 2023 over same period of last year	From the beginning of the year to the end of the Reporting Period	Increase/ decrease from the beginning of the year to the end of the Reporting Period over same period of last year
		%		%
		%		%
		%		%
				%
		%		%
		%		%
	%	%	%	%
	As at the end of the Reporting Period	As at the end of last year	Increase/decrease for the end of the Reporting Period over the end of last year	
			%	
			%	

2. Income statement items

Items	From the beginning of the year to the end of the Reporting Period	Same period of last year	Year-on-year increase/ decrease	Reasons for changes
			%	
			%	
			%	
			%	
			%	
			%	
			%	
			%	

Items	From the beginning of the year to the end of the Reporting Period	Same period of last year	Year-on-year increase/ decrease	Reasons for changes
			%	
			%	
			%	
			%	
			%	
			%	

3. Cash flow items

Items	From the beginning of the year to the end of the Reporting Period	Same period of last year	Year-on-year increase/ decrease	Reasons for changes
			4 %	
			44 %	
			%	

BUSINESS REVIEW

Heparin Industrial Chain Business



CDMO BUSINESS

OUTLOOK

II. INFORMATION OF THE SHAREHOLDERS

(1) Table of total number of ordinary shareholders, the number of preferred shareholders whose voting rights have been restored and shareholdings of the top 10 shareholders

Unit: Share(s)

Total number of ordinary shareholders as at the end of the Reporting Period		Total number of preferred shareholders (if any) whose voting rights have been restored as at the end of the Reporting Period				
Shareholding of the top 10 shareholders						
Name of shareholder	Nature of shareholder	Shareholding percentage	Number of shares held	Number of shares held subject to selling restrictions	Status of shares pledged, marked or frozen	
					Status of shares	Number
		%				
		%				
		%				
		%				
		%				
		%				
		%				
		%				
		%				
		%				

Shareholding of the top 10 shareholders who are not subject to selling restrictions			
Name of shareholder	Number of shares held not subject to selling restrictions	Type of shares	
		Type of shares	Number
Explanations of the related relationships or acting in concert among above shareholders			
Description of the top 10 shareholders' participation in financing and securities lending business (if any)			

Items	September 30, 2023	
	7,805,326,066.17	
	10,623,409.64	
	266,104,811.21	
	11,859,083,872.73	
Non-current assets:		
	–	
	–	
	1,070,390.11	
	666,685,804.22	
	515,024,324.71	
	1,054,981,140.44	
	–	
	2,150,962,742.89	
	352,770,797.25	
	–	
	–	
	118,796,156.63	
	490,667,506.89	
	53,090,539.67	
	2,423,635,646.83	
	190,843,267.93	
	154,763,710.53	
	88,275,110.64	
	8,261,477,138.74	
	20,120,561,011.47	

2. Consolidated Income Statement from the beginning of the year to the end of the Reporting Period

Currency: RMB Unit: Yuan

Items	Amount for current period	
	4,063,233,063.48	
	4,063,233,063.48	
	3,669,009,984.63	
	2,720,675,046.08	
	12,802,583.40	
	402,920,606.39	
	306,237,517.82	
	152,223,825.20	
	74,150,405.74	
	172,185,286.54	
	34,032,251.07	
	20,383,283.61	
	-274,834,971.73	
	-283,240,300.17	
	–	

3. Consolidated Cash Flow Statement from the beginning of the year to the end of the Reporting Period

Currency: RMB Unit: Yuan

Items	Amount for current period	
	4,603,550,675.54	
	206,974,609.19	
	47,790,265.82	
	4,858,315,550.55	
	3,633,091,884.41	
	673,352,520.02	
	210,215,294.50	
	575,644,822.54	
	5,092,304,521.47	
	-233,988,970.92	

Items	Amount for current period	
	1,494,880,389.45	
	32,344,822.97	
	2,323,756.31	
	–	
	771,783,056.20	
	2,301,332,024.93	
	274,837,032.45	
	683,038,740.26	
	–	
	31,117,972.12	
	988,993,744.83	
	1,312,338,280.10	
	–	
	–	
	3,557,251,571.62	
	150,342,810.61	
	3,707,594,382.23	
	4,097,326,290.58	
	250,602,018.90	
	–	
	31,764,577.78	
	4,379,692,887.26	
	-672,098,505.03	
	31,821,093.12	
	438,071,897.27	
	1,319,707,185.95	
	1,757,779,083.22	

Items	September 30, 2023	January 1, 2023	Adjustments	December 31, 2022
	7,805,326,066.17			
	10,623,409.64			
	266,104,811.21			
	11,859,083,872.73			
Non-current assets:				
	1,070,390.11			
	666,685,804.22			
	515,024,324.71			
	1,054,981,140.44			
	2,150,962,742.89			
	352,770,797.25			
	118,796,156.63			
	490,667,506.89			
	53,090,539.67			
	2,423,635,646.83			
	190,843,267.93			
	154,673,710.53			
	88,275,110.64			
	8,261,477,138.74			
	20,120,561,011.47			

Items	September 30, 2023	January 1, 2023	Adjustments	December 31, 2022
	4,997,191,595.42			
Non-current liabilities:				
	2,116,802,507.02			
	92,624,776.83			
	395,725.24			
	40,293,108.90			
	9,876,817.34			
	29,751,781.75			
	334,582,068.96			
	2,624,326,786.04			
	7,621,518,381.46			
Owners’ equity:				
	1,467,296,204.00			
	5,854,583,773.47			
	226,528,230.35			

Items	September 30, 2023	January 1, 2023	Adjustments	December 31, 2022
	545,376,458.31			
	4,312,374,190.99			
	12,406,158,857.12			
	92,883,772.89			
	12,499,042,630.01			
	20,120,561,011.47			

(3) Audit Report